Biogen announced that it will present 14 abstracts on its nephrology portfolio, including EMPAVELI (pegcetacoplan) and investigational felzartamab, at the 63rd European Renal Association Congress and the 2026 American Transplant Congress. The data cover multiple kidney diseases such as C3 glomerulopathy and antibody-mediated rejection in transplant patients, highlighting sustained efficacy and safety from recent clinical trials. These presentations underscore Biogen's expanding focus on kidney diseases and aim to advance treatment options for patients with limited therapies. The company collaborates with Sobi for EMPAVELI commercialization outside the U.S. and continues to develop felzartamab, an anti-CD38 antibody, as a potential treatment for transplant rejection and other immune-mediated kidney conditions.
Biogen's investigational drug salanersen received FDA Breakthrough Therapy Designation for treating spinal muscular atrophy (SMA), based on Phase 1b study results showing improved motor function and slowed neurodegeneration in children with suboptima...
Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement that its Phase 2 CELIA study for an Alzheimer's drug missed the primary endpoint. Despite Biogen calling the results "compelling," the stoc...
UCB and Biogen announced positive Phase 3 trial results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE). The drug, combined with standard care, significantly improved disease activity at 48 weeks compared to ...
